Effects Of Rosiglitazone On Bone Mineral Density In Post-menopause Women:a Meta-analysis

Objectives:Previous researches demonstrate less stringent effect of thiazolidinediones on bone mineral density (BMD).we decided to perform a meta-analysis about the effects of rosiglitazone on BMD.Methods:In this meta-analysis, searches of Medline, Embase, Cochrane Library, Chinese biological medical database were undertaken to identify studies in humans of the association between rosiglitazone and BMD.Results:Fixed effects model was used for this meta-analysis. The results of our research were reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A total of5studies with354cases were included in our research. Our meta-analysis showed that the exposure of rosiglitazone was associated with significant decline in bone mineral density at the lumbar spine, total hip and femoral neck, but for the patient with type2diabetes mellitus(T2DM) total hip BMD didn’t decrease significantly between rosiglitazone and control group,4RCTs studied total hip areal BMD,3RCTs of the patient are T2DM, In this pooled analysis, the decreases in the total hip BMD values were not significant between RSG and control group (WMD=-0.66,95%CI:-1.43-0.11, p=0.10,n=253). When incorporated data of another article, the difference was significant (WMD=-1.05,95%CI:-1.66-0.43, p=0.0008,n=303).Conclusion:Our study include studies acquire high score except one the major limitation of this study was the small number of patient included but sufficient, the changes of bone metabolic markers by the treatment of rosiglitazone were not include in this study.Large prospective double-blind randomized placebo-controlled studies with long-term follow-up should be performed in the near future to further assess the effects of rosiglitazone on osteoporotic patients, mainly postmenopausal women. Clinical applications need to be cautious for rosiglitazone.